A Single-Center, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine (RBP-6000) Using Poly (DL-lactide-co-glycolide) Polymer of Two Different Molecular Weights (Low and High Molecular Weights as Test Treatments) in Comparison to Intermediate Molecular Weight (Reference Treatment) in Treatment-Seeking Subjects With Opioid Use Disorder

Trial Profile

A Single-Center, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine (RBP-6000) Using Poly (DL-lactide-co-glycolide) Polymer of Two Different Molecular Weights (Low and High Molecular Weights as Test Treatments) in Comparison to Intermediate Molecular Weight (Reference Treatment) in Treatment-Seeking Subjects With Opioid Use Disorder

Completed
Phase of Trial: Phase I

Latest Information Update: 25 May 2016

At a glance

  • Drugs Buprenorphine/naloxone (Primary)
  • Indications Opioid abuse
  • Focus Pharmacokinetics
  • Sponsors Indivior; Reckitt Benckiser
  • Most Recent Events

    • 12 May 2016 Status changed from active, no longer recruiting to completed.
    • 10 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 28 Dec 2015 Planned End Date changed from 1 May 2016 to 1 Jul 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top